Cue Biopharma (NASDAQ:CUE) CEO Sells $305,446.85 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 11,087 shares of Cue Biopharma stock in a transaction on Monday, October 12th. The stock was sold at an average price of $27.55, for a total transaction of $305,446.85. Following the completion of the transaction, the chief executive officer owned 694,908 shares in the company, valued at approximately $19,144,715.40. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96.
• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The stock was sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Stock Performance

NASDAQ CUE traded down $0.97 during trading on Wednesday, hitting $18.60. 244,958 shares of the company’s stock traded hands, compared to its average volume of 475,854. The stock has a fifty day moving average of $27.73 and a two-hundred day moving average of $72.25. Cue Biopharma, Inc. has a 12-month low of $4.97 and a 12-month high of $45.50.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. On average, equities analysts forecast that Cue Biopharma, Inc. will post -21.79 EPS for the current year.

Institutional Investors Weigh In On Cue Biopharma

Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC lifted its holdings in Cue Biopharma by 301.8% in the second quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock worth $809,000 after buying an additional 38,333 shares during the period. Seven Fleet Capital Management LP bought a new stake in Cue Biopharma during the 2nd quarter valued at approximately $338,000. Bank of America Corp DE purchased a new position in shares of Cue Biopharma during the 2nd quarter worth approximately $219,000. ADAR1 Capital Management LLC purchased a new position in shares of Cue Biopharma during the 2nd quarter worth approximately $1,742,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Cue Biopharma during the 2nd quarter worth approximately $83,000. Institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. B. Riley Financial initiated coverage on Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 price target on the stock. Wall Street Zen downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Weiss Ratings downgraded Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Finally, Zacks Research raised Cue Biopharma to a “hold” rating in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $83.00.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.